Anova Recognizes 1,500 Prostate Cancer Patients Treated with Accuray CyberKnife

Anova Recognizes 1,500 Prostate Cancer Patients Treated with Accuray CyberKnife
Anova Cancer Care, in Colorado, recently announced that it has treated 1,500 prostate cancer patients using the CyberKnife System, a radiation therapy device designed to deliver stereotactic body radiation therapy (SBRT), an advanced form of high-dose radiation, directly to the tumor to minimize damage to nearby healthy tissue. "We use the CyberKnife for prostate cancer because it offers distinct advantages when treating this disease; most notably it's the only system available with the ability to track movement of the prostate and automatically adjust the radiation beam during treatment," Lee K. McNeely, MD, radiation oncologist at Anova Cancer Care, said in a press release. "The CyberKnife System's accuracy is sub-millimeter, enabling my colleagues and me to treat the disease with unparalleled preservation of healthy tissue and provide substantial quality of life and lifestyle benefits to patients.” A study led by the device's developer, Accuray, and presented at the
Subscribe or to access all post and page content.